The Efficacy of Adjuvant Targeted Therapy in Patients with Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

Background: The aim of this systematic evaluation and meta-analysis was to analyze the efficacy and adverse effects of adjuvant targeted therapy regimens in advanced or metastatic renal cell carcinoma (RCC). Methods: Studies eligible for the efficacy of adjuvant targeted therapy regimens in advanced or metastatic RCC published before December 2021 in PubMed, Embase, Cochrane Clinical Trials Database (CENTRAL), and Web of Science were searched for (1) patients with locally advanced renal cell carcinoma (RCC) who received adjuvant postoperative targeted therapy versus those not receiving active treatment; (2) primary endpoint outcomes of disease-free survival (DFS), overall survival (OS), and adverse events (AEs); and (3) design: randomized controlled trial (RCT) as inclusion criteria. Data on DFS and OS were extracted or recalculated by meta-analysis as hazard ratios (HRs), and AEs were compared using a dominance ratio (OR). Result: This systematic evaluation will provide evidence on the effectiveness and adverse effects of adjuvant targeted therapy in patients with advanced RCC. The results of meta-analysis showed that all of the three adjuvant targeted therapeutic drugs (sorafenib, sunitinib, and pazopanib) did not benefit from the adjuvant targeted therapy for DFS and OS and even increase the incidence of AEs compared to the placebo. Conclusions: The aim of this study was to summarize data on DFS, OS, and AEs in patients with advanced RCC treated with targeted therapies. The evidence provided by this systematic evaluation and meta-analysis will help guide clinical decision-making and provide insight into the future management of patients with advanced RCC.

[Determination of phenylethanolamine A residue in feeds by ultra performance liquid chromatography-tandem mass spectrometry].

A method was developed for the determination of the residue of phenylethanolamine A in feeds by ultra performance liquid chromatography-triple quadrupole mass spectrometry (UPLC-MS/MS). The phenylethanolamine A in sample was extracted with phosphoric acid methanol solution. The extract was purified and concentrated by an MCX column. In the positive mode, an ultra-performance BEH C18 column (100 mm x 2.1 mm, 1.7 microm) was used to separate the phenylethanolamine A, and the separation was carried out on a Waters UPLC system by using gradient elution with acetonitrile and 0.1% (v/v) formic acid aqueous solution as the mobile phases at a flow rate of 0.4 mL/min. The qualitative and quantitative analysis was carried out by multi-reaction monitoring (MRM) mode, in which the analyte was ionized by electrospray ionization interface (ESI). The results showed that, the calibration curve was linear in the range of 0.5-100 microg/kg (r > 0.999), the limit of quantification (S/N > 10) was 10 microg/kg, the recoveries ranged from 79.6% to 86.2%, and the relative standard deviations (RSDs) were between 3.1% and 6.7%. The real sample tests showed that the method is convenient and reliable.